342 related articles for article (PubMed ID: 10486695)
1. Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
Zusman RM; Chesebro JH; Comerota A; Hartmann JR; Massin EK; Raps E; Wolf PA
Clin Cardiol; 1999 Sep; 22(9):559-73. PubMed ID: 10486695
[TBL] [Abstract][Full Text] [Related]
2. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Tran H; Anand SS
JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
4. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Montalescot G
Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel for cerebrovascular prevention.
Paciaroni M; Bogousslavsky J
Cerebrovasc Dis; 1999; 9(5):253-60. PubMed ID: 10473907
[TBL] [Abstract][Full Text] [Related]
6. Dual antiplatelet therapy for prevention of recurrent ischemic events.
Nappi J; Talbert R
Am J Health Syst Pharm; 2002 Sep; 59(18):1723-35. PubMed ID: 12298110
[TBL] [Abstract][Full Text] [Related]
7. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
CAPRIE Steering Committee
Lancet; 1996 Nov; 348(9038):1329-39. PubMed ID: 8918275
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel: a review of its use in the prevention of atherothrombosis.
Jarvis B; Simpson K
Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738
[TBL] [Abstract][Full Text] [Related]
9. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
Hankey GJ; Sudlow CL; Dunbabin DW
Stroke; 2000 Jul; 31(7):1779-84. PubMed ID: 10884487
[TBL] [Abstract][Full Text] [Related]
10. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
11. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
13. Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
Davis KA; Miyares MA; Dietrich E
Am J Health Syst Pharm; 2015 Oct; 72(19):1623-9. PubMed ID: 26386103
[TBL] [Abstract][Full Text] [Related]
14. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Ringleb PA; Bhatt DL; Hirsch AT; Topol EJ; Hacke W;
Stroke; 2004 Feb; 35(2):528-32. PubMed ID: 14739421
[TBL] [Abstract][Full Text] [Related]
15. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet therapy in populations at high risk of atherothrombosis.
Faxon DP; Nesto RW
J Natl Med Assoc; 2006 May; 98(5):711-21. PubMed ID: 16749646
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Topol EJ;
Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
[TBL] [Abstract][Full Text] [Related]
18. Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
Ferguson JJ; Gonzalez ER; Kannel WB; Olin JW; Raps EC
Clin Ther; 1998; 20 Suppl B():B42-53. PubMed ID: 9589830
[No Abstract] [Full Text] [Related]
19. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events.
Caro JJ; Migliaccio-Walle K
Am J Med; 1999 Dec; 107(6):568-72. PubMed ID: 10625025
[TBL] [Abstract][Full Text] [Related]
20. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Mohler ER
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
